A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403

被引：0

作者：

Naohiro Oda

Kastuyuki Hotta

Kiichiro Ninomiya

Daisuke Minami

Eiki Ichihara

Toshi Murakami

Toshihide Yokoyama

Hirohisa Ichikawa

Kenichi Chikamori

Nagio Takigawa

Nobuaki Ochi

Shingo Harita

Yoshinobu Maeda

Katsuyuki Kiura

机构：

[1] Okayama University Hospital,Department of Allergy and Respiratory Medicine

[2] Okayama University Hospital,Center for Innovative Clinical Medicine

[3] National Hospital Organization Okayama Medical Center,Department of Respiratory Medicine

[4] Himeji Red Cross Hospital,Department of Respiratory Medicine

[5] Onomichi City Hospital,Department of Respiratory Medicine

[6] Kurashiki Central Hospital,Department of Respiratory Medicine

[7] KKR Takamatsu Hospital,Department of Respiratory Medicine

[8] National Hospital Organization Yamaguchi Ube Medical Center,Department of Medical Oncology

[9] Kawasaki Medical School,Department of General Internal Medicine 4

[10] Okayama Saiseikai General Hospital,Department of Respiratory Medicine

[11] Chugoku Central Hospital,Department of Respiratory Medicine

[12] Okayama University Graduate School of Medicine,Department of Hematology, Oncology and Respiratory Medicine

[13] Dentistry,undefined

[14] and Pharmaceutical Sciences,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 82卷

关键词：

Non-small-cell lung cancer; EGFR mutation; Afatinib; EGFR-TKI; Readministration; T790M;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1031 / 1038

页数：7

共 472 条

[1]

Mitsudomi T(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial Lancet Oncol 11 121-128

[2]

Morita S(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[3]

Yatabe Y(2012)Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial Lancet Oncol 13 239-246

[4]

Negoro S(2012)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomized, phase 3 study Lancet Oncol 12 735-742

[5]

Okamoto I(2013)Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 3327-3334

[6]

Tsurutani J(2014)Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 213-222

[7]

Seto T(2004)Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 22 3852-3859

[8]

Satouchi M(2004)Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Ann Oncol 15 1782-1789

[9]

Tada H(2007)Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer J Thorac Oncol 2 96-948

[10]

Hirashima T(2007)Recent improvement in the survival of patients with advanced non small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy Cancer 109 939-1123

← 1 2 3 4 5 6 7 8 9 10 →